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Abstract
Background: All cancer arise as a result of a somatic mutation, several models have been developed to
understand cancer, it has been seen as an evolutionary process in which somatic mutations are the pieces of
the puzzle. Somatic mutation catalogue of the cancer genome has been used to reconstruct cancer phylogeny,
in this case somatic mutations without selective pressure will help determine the age of a tumor.
Results: Any type of mutation can have an impact on the cell, the majority of them are neutral, mutations
that have less functional impact, that means less selective pressure on the tumor evolution are the ones used as
temporal measurement of the tumors. A positive correlation was found between two types of measurements,
which shows that an appropriate age can be extracted using both of them.
Conclusion: The use of this method can be coupled with other cancer analysis, for example, along with
co-occurrence and mutual exclusivity analysis could bring a better understanding of the tumor, an appropriate
tumor classification and with this a more accurate clinical decision, which leads to an efective treatment.
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Background
Every cell in the body is a direct descendant of the fer-
tilized egg from which each of us developed. Through
time the DNA sequence of every cell acquires a set
of differences from its progenitor, this variations are
called somatic mutations [1, 2]. All cancer arise as a
result of a somatic mutation, so an approach to un-
veil the mysteries of cancer is through the catalogue of
mutations a cancer genome has [1, 3].
Somatic mutations have been classified depending on
certain characteristics, such as location, mutations can
occur all over the genome, that can be a simple way to
determine if they will affect the protein structure and
a basic approach to determine the functional impact
the variation will have [4, 5, 6]. In cancer is important
to classify mutations as the ones that have been posi-
tively selected or “driver” mutations, which confer an
advantage to the cell and “passenger” mutations, this
type haven’t been selected, they just happened to be
there [1, 3].
To understand cancer, several models have been de-
veloped, it has been seen as an evolutionary process, it
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is a series events, constant acquisition of mutations and
natural selection, these processes mark the genome,
and a cancer’s life history is encrypted in the somatic
mutations that we can find in its genome [7, 8, 2].
Knowing the history of a tumor is important, be-
cause as in evolution, it lets us understand the subpop-
ulations of cells present in a tumor and the biological
processes, and can be used in a clinical decision [9]. In
fact the catalogue of mutations have been used to tell
the history of tumors, to reconstruct a phylogeny of
the diverse clone subpopulations, which its being rec-
ognized to have value making clinical decisions [10, 11].
An important thing in history is time, knowing how
long have been the tumor evolving can help in diag-
nosis, tumor classification, prognosis and treatment.
The approach described to determine the age of a tu-
mor based on somatic mutations with low or neutral
selective pressure can help to understand mutational
process like co-occurrence and mutual exclusivity, that
can lead to new functional interactions, which are im-
portant not only for understanding cancer, but also in
clinical decisions, it can help in the selection of multi
targeted anti-tumor therapies, co-mutations suggest
combination of drugs might be effective while mutual
exclusion indicate combinations likely won’t work, this
is specially important because treatments focusing in
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a unique alteration can lead to a single cell that is
resistant to therapy proliferates, followed by relapse,
increasing the mortality [1, 12, 13].
Studies show that the accumulation of mutations can
be accelerated due to genome instability, increased sen-
sitivity to mutagenic agents and breakdown of genomic
maintenance [14, 15], according to this we can make
the assumption that the mutations present before the
tumor started to evolve are negligible in number.
The majority of molecular changes are caused by
random fixation of selectively neutral mutants [16],
correspondingly in cancer the majority of mutations do
not confer advantage, it means they are not detectable
under selection [17, 18]. Knowing this we can assume
passenger mutations are useful to determine the age of
a tumor because most mutations in the cancer genome
are of this kind.
As the evolutive history, the age of a tumor can be
inferred from the catalogue of mutations, in this paper
we will present a method to determine the age of a
tumor in terms of the somatic mutations with low or
no selection pressure present in the cancer genome.
Methods
Data
All data used in this paper is available on line. The
dataset used in this paper is breast invasive carcinoma
mutation assessor analysis results [19]. Mutation as-
sessor is a server that predicts the functional impact
of amino-acid substitutions in proteins, such as muta-
tions discovered in cancer or missense polymorphisms.
The functional impact is assessed based on evolution-
ary conservation of the affected amino acid in protein
homologs.
Data preprocess
Data was subjected to an analysis under the scope of
the project objectives to select the variables that could
be used to determine the age of the tumor. From 356
variables, nine were selected. The variables selected
helped us know different characteristics of the muta-
tion including: location, classification and functional
impact [6]. The data was analyzed and the outliers
were identified by box and whiskers plots, and appro-
priately managed with the interquartile range (IQR)
method, those samples that where below quantile 25
minus 1.5∗IQR or above quantile 75 plus 1.5∗IQR were
not taken into account, leaving 800 samples.
Data process
Various measurements based on the count of passen-
ger mutations were performed. Variant classification
was the selection criteria to determine the mutations
as passenger, the measurements consisted on counting
the occurrence of a certain type of mutation by sam-
ple. Based on the location of the mutation and the
functional impact score (FIS) determined by [6], we
took the ones that might have low or neutral functional
impact, from the classifications presented in table 1.
Silent, intergenic region (IGR), intron mutations (int)
and missense mutations with less than 1.9 functional
impact score (FIS) [6], were selected as the ones that
could have least impact on the cell function and have
less selective pressure on the tumor evolution, and so
the ones to be used as temporal measurement of the
tumor.








medium - high [21]
In frame indels Non-synonymous
medium - high [21]
Frame shift indels Non-synonymous
medium - high [21]
Start codon indels Affects translation
medium-high
Stop codon indels Affects translation
medium-high
Splice site Affects translation
medium - high
Intergenic regions Non-coding
neutral - low [1]
Intron Non-coding
neutral - low [1]
De Novo start out of frame Non-synonymous
medium-high
De Novo start in frame Non-synonymous
medium-high
5’ Flank Non-coding, gene expression
medium-high
3’ and 5’ Untranscribed regions Non-coding, gene expression
medium-high
Table 1 Variant classifications present in the data with its
predicted impact on protein function.
Results and discussion
Although all mutations can have an impact on the
cell, the majority of them are neutral [22], so we can
assume that those mutations that do not change amino
acid in the protein sequence, that are in non coding re-
gions and/or far from known gene control regions, have
mostly low or neutral impact. Looking to the types of
mutation and its characteristics on table 1.
Silent, intergenic region (IGR), intron mutations
(int) and missense mutations with less than 1.9 func-
tional impact score (FIS) [6], were selected as the ones
that could have least impact on the cell function and
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have less selective pressure on the tumor evolution,
and so the ones to be used as temporal measurement
of the tumor.
The measurements to determine the tumor age
where used in a breast cancer mutation assessor anal-
ysis dataset [19]. For each sample, which has a unique
identification total, silent, intergenic region and intron
mutations, as well as mutations with low or neutral
functional impact (FIS < 1.9) [6] were counted with a
python algorithm developed for this purpose.
Total IGR Int Sil FI Sum
Mean 40.35 1.24 1.27 8.7 13.47 11.2
STD 24.05 0.53 0.58 5.6 8.6 5.7
Min 1 0 0 1 2 3
25% 23 1 1 5 7 7
50% 33 1 1 7 11 10
75% 53 1 1 12 18 14
Max 125 3 3 27 44 30
Table 2 General description of the data. Intergenic Regions
(IGR), Intron (Int), Silent (Sil), summation of intergenic region,
intron and silent (Sum) and low and neutral functional impact
(FI) per sample.
General statistics of the measurements, see table 2,
showed that IGR and intron mutations counts were
too low (75% of the samples has 1 mutation), with
this counts we don’t have enough information to be
used as an appropriate temporal measurement by it-
self, for this reason, the summation of intergenic, in-
tron and silent mutation was taken as a single mea-
surement, leaving us with two different measurements
to assess, low FIS (functional impact score below 1.9),
sum (summation of IGR, intron and silent mutations).
A simple linear regression was performed between
measurements, a positive correlation was found for
both regressions. The correlation between silent and
low FIS didn’t show a lot of difference with the corre-
lation between the other two measurements, because
of the similarity, summation of IGR, intron and silent,
which includes all the mutations with neutral or low
evolutionary impact was used. It’s worth to note that
the mutations counted for each measurements are only
used for that measurement, the correlation between
sum and low FIS showed an R value of 0.74, see fig-
ure 1, from which we can infer that two different types
of mutation with the same predicted low or neutral
impact on the cell are occurring similarly. A positive
correlation was also found between each measurement
and the total mutations,see figure 2 (sum vs total:
slope=0.2, R=0.85 and low FIS: slope=0.3, R=0.87)
allowing us to use them as an approach to determine
the tumor age in terms of neutral and low impact mu-
tations.
Figure 1 Sum vs Low FIS. Linear regression between
measurements, sum and low FI, R=0.74
Figure 2 Total mutations linear regressions. Linear regression
between each measurement and total mutations for sum
R=0.85 and for low FI R=0.87
The tumor with the minimum for each measure-
ment is classified as the youngest, for this dataset
it was found that a sample has three for each mea-
surement, which makes it the newest tumor. Dif-
ference between the measurements can be found,
in some cases it doesn’t let us determine the tu-
mor age (difference greater than 12), the oldest
tumor has 36 for low FIS and 26 for sum, for
the complete list of tumor ages see supplementary
data or go to the study repository available on
https://github.com/SusanaLondono/TumorAge.
Conclusion
Gigantic global efforts have lead us to understand a
little better how cancer develop and how can we fight
against it. From this hundreds of gigabytes of data
have been put available on-line. Understanding can-
cer as an evolutionary process is not new [23], but the
availability of data is recent and it has to be exploited.
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Efforts to uncover the evolutionary history of tumors
from the catalogue of mutations, mainly in driver mu-
tations, have been done. This study presents a simple
approach to determine the age of a tumor for breast
cancer, but it doesn’t mean that the method can’t be
used in other datasets of different types of cancer.
The use of this method can be coupled with other
cancer analysis, for example, along with co-occurrence
and mutual exclusivity analysis could bring a better
understanding of the tumor, an appropriate tumor
classification and with this a more accurate clinical
decision, which leads to an effective treatment.
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